Switching Gears in Retinal Disease: Real-World Expectations for Second-Generation Therapies
Multiple second-generation retinal treatments for diseases including age-related macular degeneration (AMD), diabetic eye disease, and retinal vein occlusion (RVO) are now available. Yet, real-world experience with these treatments differs from the patient cohorts and treatment criteria set forth in the clinical trials. Hear from our experts as they share how they are using second-generation retinal treatments in practice and how their experience aligns with the data surrounding these new treatments.
Episodes 1-6 of 6
Cases From the Real World: 91-Year-Old Patient With Wet AMD and a Submacular Hemorrhage
CME/CECases From the Real World: 91-Year-Old Patient With Wet AMD and a Submacular Hemorrhage
Cases From the Real World: 61-Year-Old With Wet AMD With a High Treatment Burden
CME/CECases From the Real World: 61-Year-Old With Wet AMD With a High Treatment Burden
Cases From The Real World: A Long Battle With BRVO-ME
CME/CECases From The Real World: A Long Battle With BRVO-ME
Cases From the Real World: 72-Year-Old Woman With CRVO
CME/CECases From the Real World: 72-Year-Old Woman With CRVO
Cases From the Real World: 64-Year-Old Man With Moderate NPDR
CME/CECases From the Real World: 64-Year-Old Man With Moderate NPDR
Cases From the Real World: 65-Year-Old Woman With DME and Considering Cataract Surgery
CME/CECases From the Real World: 65-Year-Old Woman With DME and Considering Cataract Surgery
- advertisement
